Novel and Innovative Approaches in the Management of Urological Tumors

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 1461

Special Issue Editor


E-Mail Website
Guest Editor
START Lisbon, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal
Interests: prostate cancer; bladder cancer; melanoma; non melanoma skin cancers; cancer clinical trials; immunotherapy; colorectal cancer; bone metastasis

Special Issue Information

Dear Colleagues,

Urological tumors represent a significant challenge in the realm of oncology, necessitating novel and groundbreaking approaches. As a Medical Oncologist who focuses on both urology and oncology, I am pleased to announce that a Special Issue of Life has been commissioned to address the latest developments in these fields.

This Special Issue aims to shed light on innovative methods for diagnosing, treating, and improving outcomes in patients with urological tumors. Topics of interest include but are not limited to the following:

  • Early Detection Techniques: Exploring cutting-edge screening programs for the early identification of urological tumors.
  • Diagnostic Tools: Introducing new diagnostic tools that enhance precision in urological cancer diagnosis.
  • Surgical Innovations: Highlighting advances in surgical approaches and techniques for both early and locally advanced urological tumors.
  • Therapeutic Technologies: Showcasing new therapeutic technologies and strategies for curative interventions in urological malignancies.
  • Targeted Therapies: Discussing systemic targeted therapies tailored to the unique characteristics of urological tumors.
  • Immunotherapies: Examining the application of immunotherapies in the personalized treatment of urological cancers.

We invite submissions of studies that contribute to facilitating a deeper understanding of the evolving landscape in urological oncology. This Special Issue aims to provide valuable insights into diagnostic and therapeutic approaches, offering readers a glimpse into the future of urological cancer management.

Your contributions will play a vital role in advancing our understanding of urological tumors and fostering innovations in their treatment. We look forward to receiving your manuscripts by the submission deadline.

Dr. André Mansinho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urological tumors
  • early detection
  • diagnosis
  • novel therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 424 KiB  
Article
Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer
by Mirko Bakula, Tvrtko Hudolin, Nikola Knezevic, Zoran Zimak, Jerko Andelic, Ilija Juric, Marija Gamulin, Milena Gnjidic and Zeljko Kastelan
Life 2024, 14(7), 789; https://doi.org/10.3390/life14070789 - 22 Jun 2024
Viewed by 1180
Abstract
Bacillus Calmette-Guérin (BCG) therapy for patients with non-muscle invasive bladder cancer (NMIBC) faces limitations in efficacy and significant side effects, aggravated by a recent global shortage. In this prospective clinical study, we report the outcomes of sequential intravesical administration of gemcitabine and docetaxel [...] Read more.
Bacillus Calmette-Guérin (BCG) therapy for patients with non-muscle invasive bladder cancer (NMIBC) faces limitations in efficacy and significant side effects, aggravated by a recent global shortage. In this prospective clinical study, we report the outcomes of sequential intravesical administration of gemcitabine and docetaxel (Gem/Doce) as a first-line treatment for BCG-naïve patients with high-risk NMIBC (HR NMIBC). From October 2019 until April 2022, we enrolled 52 patients and followed the treatment protocol set forth by the University of Iowa. Follow-up assessments were conducted every 3 months. In this cohort, 25 (48.1%) patients were diagnosed with high-grade T1 (T1HG) bladder cancer, 10 (19.2%) patients had carcinoma in situ (CIS), and 17 (32.7%) patients had a combination of T1HG+CIS. The median time to first recurrence in the T1HG, CIS, and T1HG+CIS groups was 11, 10.5, and 8.8 months, respectively. The recurrence-free survival was 98.1%, 94.2%, and 80.8% at 6, 9, and 12 months, respectively. The rate of progression-free survival was 100%, 98.1%, and 92.3% at 6, 9, and 12 months, respectively. We demonstrated the safety and efficacy of Gem/Doce therapy in BCG-naïve patients with HR NMIBC during a one-year follow-up. Further research with extended follow-ups, as well as direct comparisons of Gem/Doce with other anticancer agents, is essential. Full article
Show Figures

Figure 1

Back to TopTop